Evidence map›Paper›PMID 39991718›Full record

ArticleExperimental and therapeutic medicine2025

Harlequin syndrome in a young patient with osteosarcoma after pleural metastasectomy: A case report and a mini review of the literature.

Myrto Moutafi, Anastasios Kyriazoglou, Ioannis Kotsantis, Panagiota Economopoulou, Evgenia Efthymiou, Maria Kyrkasiadou, Anna Boulouta, Niki Gavrielatou, Evangelos Zazas, Konstantinos Markakis and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Myrto MoutafiSection of Medical Oncology, Second Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens 12462, Greece.
Anastasios KyriazoglouSection of Medical Oncology, Second Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens 12462, Greece.
Ioannis KotsantisSection of Medical Oncology, Second Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens 12462, Greece.
Panagiota EconomopoulouSection of Medical Oncology, Second Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens 12462, Greece.
Evgenia EfthymiouSecond Department of Radiology, Attikon University Hospital, Athens 12462, Greece.
Maria KyrkasiadouSection of Medical Oncology, Second Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens 12462, Greece.
Anna BouloutaSection of Medical Oncology, Second Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens 12462, Greece.
Niki GavrielatouSection of Medical Oncology, Second Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens 12462, Greece.
Evangelos ZazasSection of Medical Oncology, Second Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens 12462, Greece.
Konstantinos MarkakisSection of Internal Medicine, Second Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens 12462, Greece.
Amanda PsyrriSection of Medical Oncology, Second Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens 12462, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Harlequin syndrome is a rare autonomic disorder with at least 83 reported cases in literature, 6% of which are congenital. When the fibers responsible for sudomotor and vasomotor supply to the face at the T2-T3 level are unilaterally blocked, it leads to hemifacial discoloration. This results in one-half of the face appearing flushed and hyperemic, sharply contrasting with the pale appearance of the other half. The cause of this syndrome is unknown; however, it appears to involve an autonomic nervous system dysfunction. It can be caused by an injury, compression, or blockade of sympathetic fibers along the pathway. The present study was a case of a metastatic osteosarcoma patient with a history of video-assisted thoracic surgery pleurectomy that presented in Attikon University Hospital (Athens, Greece) with worsening dyspnea and right-sided facial flushing.

Indexed as

harlequin syndromehemifascial discolorationosteosarcoma

Identifiers

PMID39991718
PMCPMC11843204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.